This page is updated frequently with new Peptide-related patent applications.
| Supercapacitor configurations with graphene-based electrodes and/or peptide|
One embodiment is an edlc with a capacitor cell that includes two electrodes of opposite polarity aligned in parallel, and a peptide separator disposed between the electrodes. The separator may be a peptide coating on an electrode surface.
Elbit Systems Land And C4i Ltd.
| Diagnosis of a neurological disease|
The present invention concerns subject matter connected to or making use of lglon5, lglon5 fragments and variants of lglon5 and lglon5-fragments. In particular the present invention relates to a use of a polypeptide comprising one or more sequences of iglon5, an lglon5-fragment or a variant thereof for the diagnosis of a disease, in vitro methods for diagnosing such a disease, a polypeptide comprising one or more sequences of lglon5, an lglon5-fragment or a variant thereof or a nucleic acid encoding said polypeptide for use in the treatment of a disease, a pharmaceutical composition comprising such polypeptide, a method for treating such a disease, an autoantibody binding to iglon5, an lglon5-fragment or a variant thereof, a method for isolating such autoantibody, a medical or diagnostic device comprising such autoantibody or such polypeptide and a test kit for the diagnosis of a disease, which test kit comprises such autoantibody and/or such polypeptide..
Hospital ClÍnic De Barcelona
| Method for the quantitative characterization of amyloid and/or aggregating peptides and/or proteins in a sample|
A method for the quantitative characterization of amyloid and/or aggregated peptides and/or proteins in a sample, comprising: providing a sample, wherein the sample includes an amyloid and/or aggregated peptide and/or protein having at least one aggregate size and shape; adding an active ingredient to be analyzed to the sample solution; separating the amyloid and/or aggregated peptides and/or proteins are from one another according to their aggregate size and shape; optionally completely denaturing the amyloid and/or aggregated peptides and/or proteins of a particular fraction into monomer building blocks; determining the change in concentration of the peptide and/or protein building blocks in at least one fraction by comparison against control values without the active ingredient.. .
Forschungszentrum JÜlich Gmbh
| Compositions and methods for analysis of protein sequences and post-translational modifications|
The application discloses, compositions, methods, systems, and apparatuses for rapid sequence analysis of proteins, including location of post-translational modifications and disulfide bonds, is described. Limited digestion of fully denatured antibody occurs in seconds by flowing sample in 8 m urea at constant pressure through a micro column reactor containing immobilized aspergillopepsin i, resulting in a product mixture containing 3-10 kda peptides, which is then fractionated by capillary column chromatography and analyzed by both electron transfer dissociation (etd) and collision activated dissociation mass spectrometry.
University Of Virginia Patent Foundation
| Fluoroimmunoassay method|
An object is to provide an immunoassay method requiring neither a solid-phase immobilization step nor a washing step, enabling quick and simple quantitative measurement of a target substance in a liquid phase and capable of visualizing an antigen. Such an object is attained by measuring the concentration of a target antigen present in a test substance by sequentially performing a step (a) of bringing an antibody light-chain variable region polypeptide and an antibody heavy-chain variable region polypeptide labeled with a fluorescent dye into contact with an antigen in a test substance in a liquid phase; or bringing an antibody heavy-chain variable region polypeptide and an antibody light-chain variable region polypeptide labeled with a fluorescent dye into contact with an antigen in a test substance in a liquid phase; a step (b) of measuring the fluorescence intensity of the fluorescent dye; and a step (c) of computationally obtaining the level of the antigen contained in the test substance with reference to a positive correlation between the concentration of the antigen in a liquid phase and the fluorescence intensity of the fluorescent dye..
Ushio Denki Kabushiki Kaisha
| Insulin receptor substrate 1 (irs1) protein srm/mrm assay|
The current disclosure provides for specific peptides from the insulin receptor substrate 1 (irs1) protein and the derived ionization characteristics of those peptides that are particularly advantageous for quantifying the irs1 directly in formalin fixed biological samples by the method of selected reaction monitoring (srm) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells.
Expression Pathology, Inc.
| Methods for diagnosing diseases associated with human signal peptide-containing molecules|
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
| Quantifying her2 protein for optimal cancer therapy|
Improved methods of treatment are provided for patients suffering from cancer. The methods identify whether a tumor will be responsive to treatment with a therapeutic regime that includes anti-her2 therapeutic agents.
Expression Pathology, Inc.
| Aggregation-induced emission luminogen having an peptide sequence and its uses thereof|
A fluorescence molecular probe having a hydrophilic polypeptide backbone conjugated with a hydrophobic alkyl chain and a function group with aggregation induced emission is disclosed. The hydrophilic peptide sequence renders dna binding capacity and the hydrophobic alkyl chain provides capacity for embedding within cell membrane.
| Novel reporter constructs for compound screening|
The instant description provides reporter constructs, transgenic cells, and transgenic organisms and methods for identifying agents that can regulate gene expression and improve plant performance and yield. Compounds that increase plant performance or yield are identified by contacting a test compound with a plant cell that comprises a target promoter sequence operably linked to a polynucleotide sequence encoding a dna sequence-specific transactivator, and a reporter polynucleotide that is operably linked to a promoter sequence that is recognized by the dna sequence-specific transactivator.
Koch Biological Solutions, Llc
Systems and devices for protease detection based on engineered polymers and biopolymers and methods of use
The presently disclosed subject matter relates to modular peptide-substrate protease assays, in particular low cost and reliable methodology for measurement of protease and other enzyme activity that may be detected by optical turbidimetry or visual observation. The presently disclosed subject matter also relates to methods of using the disclosed assays within methods of detecting and monitoring diseases, methods of drug discovery, as well as in detection devices and systems..
The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences..
Boehringer Ingelheim International Gmbh
Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield, biomass, oil content and/or growth rate
Provided are isolated polynucleotides which comprise a nucleic acid sequence encoding a polypeptide which exhibits at least 94% sequence identity to seq id no: 333, and nucleic acid constructs, plants and methods of using same for increasing a yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance, and/or nitrogen use efficiency of a plant.. .
Plants having one or more enhanced yield-related traits and a making the same
Plants having one or more enhanced yield-related traits and a method for making the same are provided. It relates generally to the field of molecular biology and concerns a method for enhancing various economically important yield-related traits in plants.
Basf Plant Science Company Gmbh
Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
Provided are method of increasing oil content, growth rate, biomass, yield and/or vigor of a plant. The methods are effected by upregulating in the plant an expression level of a polypeptide comprising an amino acid sequence at least 90% homologous to the amino acid sequence selected from the group consisting of seq id nos: 199, 166-198, 200-221, 229-307, 311-330, 351-353, 355-361, 363-364, 366-368, 218, 222-228, 308-310, 350, 354, 362, 365, 523-649, 786-920, 1047 and 1048.
Ribozyme with trna synthetase activity and methods of manufacturing and using the same
Ribozymes exhibiting trna synthetase activity and substrate specificity, as well as methods for engineering and producing the same, are disclosed. The ribozymes of the present disclosure comprise a t-box rna module fused with a flexizyme module.
Purdue Research Foundation
Pipecolinic acid 4-hydroxylase and producing 4-hydroxy amino acid using same
(c) a polypeptide having an amino acid sequence that is not less than 80% identical to the amino acid sequence represented by seq id no:2, 4, 6, 8, 10, 12, 16, or 18, and having pipecolic acid 4-hydroxylase activity.. .
Method of screening lactate dehydrogenase mutant, lactate dehydrogenase mutant, polynucleotide, vector, microorganism including the mutant, and producing lactate using the microorganism
A method of screening a microorganisim having a mutant lactate dehydrogenase with increased activity, a mutant lactate dehydrogenase polypeptide, a polynucleotide and vector encoding same, and a microorganism that expresses the lactate dehydrogenase mutant, and a method of producing lactate using the microorganism.. .
Samsung Electronics Co., Ltd.
Culture medium for hematopoeitic stem cells and the applications thereof as well as the stem cells culture method
The present invention discloses a culture medium for hematopoietic stem cells and the applications thereof as well as the stem cells culture method, which adopts amino acids, vitamins, salts, lipids, protein polypeptides and cytokines, together with one or several of trace elements, small organic molecules, hematopoietic stem cell proliferation agents, plant extracts and animal tissue cell extracts, to compose the hematopoietic stem cell culture medium, which can quickly proliferate different species of cd34+ cells, and improve both the proliferation speed and telomere length of cd34+ cells significantly; also, hematopoietic stem cells cultured in the hematopoietic stem cell culture medium described in the present invention may keep their cell functions as well, achieve the functions include but not limited to anti-tumor, anti-aging, and extending lives, thus having a pretty good application prospect.. .
China Life Science Technology Group Limited
Protein coated polymeric substrate
The present invention provides a method for the functionalization of a polymeric surface with a protein by physical adsorption. The method enables a membrane spanning protein to be used as an anchor for proteins and/or peptides for display.
Orla Protein Technologies Limited
Antibodies that bind novel pcsk9 variants
The present invention provides novel polynucleotides encoding pcsk9b and pcsk9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides.
Bristol-myers Squibb Company
Antibodies comprising chimeric constant domains
Antibodies, antigen-binding proteins and fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric fc-containing antibodies, antigen-binding proteins and fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric fc-containing proteins are provided..
Regeneron Pharmaceuticals, Inc.
Compositions and methods for immunomodulation in an organism
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
This invention relates to ly6g6f, vsig10, tmem25 and lsr proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble ly6g6f, vsig10, tmem25 and lsr molecules, extracellular domains of ly6g6f, vsig10, tmem25 and lsr and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.
Peptide mimotopes of claudin 18.2 and uses thereof
The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (cldn18.2). These molecules compete with cldn18.2 for binding to a cldn18.2 binding domain, e.g.
Jpt Peptide Technologies Gmbh
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
This invention relates to vstm5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune related disorders, immunotherapy, treatment of cancer, infectious disorders and/or sepsis.. .
The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes.
Boehringer Ingelheim International Gmbh
Novel glucagon analogues
The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s
Compositions and methods for treating acute and chronic pain by local antagonism of cgrp receptors, or combination with sodium channel inhibition or with anti-inflammatory agents
The present invention provides compositions, and methods for local administration of certain peptides or combination with certain small molecules that produce analgesia and anti-inflammation in a mammal. Exemplary polypeptides provide peripheral analgesia and anti-inflammation when administered via local topical, subcutaneous, intradermal, or intranasal administration, to provide analgesia and anti-inflammation.
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh
Targeting p53 and its dna-binding domain
Disclosed are peptides comprising a full length p53 or a partial p53 and a mitochondrial targeting signal. Also disclosed are nucleic acids that encode peptides comprising a full length p53 or a partial p53 and a mitochondrial targeting signal.
University Of Utah Research Doundation
Oligomerization domain of p53 to bypass the dominant-negative effect of mutant
Disclosed are peptides comprising a partial p53 peptide and a mutated bcr coiled-coil domain. Also disclosed are nucleic acid sequences capable of encoding a peptide comprising a partial p53 peptide and a mutated bcr coiled-coil domain.
University Of Utah Research Foundation
Tau peptides, anti-tau antibodies, and methods of use thereof
Isolated tau peptides, and compositions comprising the peptides are disclosed. Further provided are antibodies specific for an isolated tau peptide.
Peptides derived from ncapg2 and their use
Ncapg2, a component of condensin complex ii, protein and novel peptides derived from the protein are provided. The peptide may include a fragment of the ncapg2 protein.
National Cancer Center
Short peptide-based therapeutic agent and medicinal composition including the same for inhibiting activities of cancer cells
The present invention relates to a short peptide-based therapeutic agent and a medicinal composition including the same for inhibiting activities of cancer cells, which includes at least one short peptide listed as seq id nos: 1 and 2, either of which is unglycosylated and has no more than 40 amino acid residues, thereby specifically reducing or inhibiting activities of cancer cells such as the cancer cell proliferation, cancer stemness, cell migration, cancer cell invasion, metastasis or drug resistance.. .
National Cheng Kung University
Mhc class i epitope delivering polypeptides and cell-targeted molecules for direct cell killing and immune stimulation via mhc class i presentation and methods regarding the same
The present invention is directed to t-cell epitope delivering polypeptides which deliver one or more cd8+ t-cell epitopes to the mhc class i presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded t-cell epitopes and are de-immunized. The present invention provides cell-targeted, cd8+ t-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections.
Molecular Templates, Inc.
Neisseria meningitidis composition and methods thereof
In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to seq id no: 68. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated orf2086 polypeptide from neisseria meningitidis serogroup b, and at least one conjugated capsular saccharide from a meningococcal.
Ang-(1-7) derivative oligopeptides and methods for using and producing the same
The present invention provides oligopeptides, in particular, ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment..
The Arizona Board Of Regents On Behalf Of The University Of Arizona
Biologically cleavable tetrapeptide linking agents
Tetrapeptide linkers for reversibly linking a first compound to a amine-containing second compound are described. Compounds containing the tetrapeptide linkers and methods of using the tetrapeptide linkers are also described..
Arrowhead Madison Inc.
On-column viral inactivation methods
The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low ph and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide..
Biogen Ma Inc.
Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
The present invention relates to improved methods in the separation recombinant polypeptides with post-translational modifications from complex mixtures through the use of a cation exchange medium.. .
Biogen Ma Inc.
Synthesis of duocarmycin analogues
A novel fmoc protected duocarmycin subunit and utilisation as a reagent in solid phase protein synthesis methodology. Also provided is a novel method of solid phase peptide synthesis, and in particular a method for the production of novel intermediates and novel monomeric and extended duocarmycin analogues having amino acid substituents..
University Of East Anglia
Follow us on Twitter
This listing is a sample listing of patent applications related to Peptide for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Peptide with additional patents listed. Browse our RSS directory or Search for other possible listings.